APOB antibody
Quick Overview for APOB antibody (ABIN7265635)
Target
See all APOB AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Purpose
- ApoB Rabbit mAb
-
Cross-Reactivity
- Mouse, Rat
-
Characteristics
- Monoclonal Antibodies
-
Purification
- Affinity purification
-
Immunogen
- A synthesized peptide derived from human ApoB
-
Isotype
- IgG
-
-
-
-
Application Notes
- WB,1:500 - 1:2000
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- PBS with 0.02 % sodium azide,0.05 % BSA,50 % glycerol, pH 7.3.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Store at -20°C. Avoid freeze / thaw cycles.
-
-
- APOB (Apolipoprotein B (APOB))
-
Alternative Name
- APOB
-
Background
- This gene product is the main apolipoprotein of chylomicrons and low density lipoproteins. It occurs in plasma as two main isoforms, apoB-48 and apoB-100: the former is synthesized exclusively in the gut and the latter in the liver. The intestinal and the hepatic forms of apoB are encoded by a single gene from a single, very long mRNA. The two isoforms share a common N-terminal sequence. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA->UAA), resulting in the creation of a stop codon, and early translation termination. Mutations in this gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective apoB, diseases affecting plasma cholesterol and apoB levels. [provided by RefSeq, Jul 2008],FLDB, LDLCQ4, apoB-100, apoB-48,Cancer,Cardiovascular,Cardiovascular diseases,Cardiovascular diseases_Heart disease,Endocrine & Metabolism,Heart,Lipid Metabolism,Lipid Metabolism_Cholesterol Metabolism,Lipids,Lipids_Lipoproteins/Apolipoproteins,Signal Transduction,APOB
-
Molecular Weight
- 515kDa
-
Gene ID
- 338
-
UniProt
- P04114
-
Pathways
- Lipid Metabolism
Target
-